XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Commitments and Contingencies | 6 Months Ended
--- | ---
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract] |
Commitments and Contingencies | Commitments and Contingencies Leases The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company’s operating leases have term end dates ranging from 2024 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2024 to 2026. Effective February 2024, the Company renewed an existing operating lease with an end date through 2026. In April 2024, in connection with the revised operating plan, the Company notified the lessor that it would terminate the lease effective August 2024. In July 2024, the Company entered into an amendment extending the termination of the lease to June 2025 with an option to extend to December 2025. The Company’s operating and finance lease right-of-use (ROU) assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components. The Company carries laboratory equipment from failed sale leasebacks, as property and equipment, net on the accompanying unaudited interim consolidated balance sheets. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. As of June 30, 2024, the Company had a $2.0 million financing liability recorded in other current liabilities and other long-term liabilities on the unaudited interim consolidated balance sheets. The elements of the lease costs were as follows (in thousands):
| Six Months Ended June 30,
| 2024 |  | 2023
Operating lease cost | $ | 3,154 |  |  | $ | 2,875 |
Finance lease cost: |  |  |
Amortization of lease assets | 1,008 |  |  | 593 |
Interest on lease liabilities | 159 |  |  | 88 |
Total finance lease cost | 1,167 |  |  | 681 |
Variable lease cost | 672 |  |  | 653 |
Total lease cost | $ | 4,993 |  |  | $ | 4,209 |
Lease term and discount rate information related to leases was as follows:
| June 30,
| 2024 |  | 2023
Weighted-average remaining lease term (in years) |  |  |
Operating leases | 2.5 |  | 2.2
Finance leases | 1.4 |  | 1.7
Weighted-average discount rate |  |  |
Operating leases | 9.8 | % |  | 9.6 | %
Finance leases | 9.0 | % |  | 9.0 | %
Supplemental cash flow information was as follows (in thousands):
| Six Months Ended June 30,
| 2024 |  | 2023
Cash paid for amounts included in the measurement of lease liabilities: |  |  |
Operating cash used in operating leases | $ | 3,203 |  |  | $ | 2,584 |
Operating cash used in finance leases | $ | 159 |  |  | $ | 88 |
Financing cash used in finance leases | $ | 906 |  |  | $ | 213 |
Future maturities of lease liabilities were as follows as of June 30, 2024 (in thousands):
| Operating Leases |  | Finance Leases
Fiscal year ending: |  |  |
2024 (remaining six months) | $ | 1,177 |  |  | $ | 631 |
2025 | 219 |  |  | 1,261 |
2026 | 226 |  |  | 20 |
2027 | 233 |  |  | — |
2028 | 240 |  |  | — |
Thereafter | 184 |  |  | — |
Total future minimum payments | 2,279 |  |  | 1,912 |
Less imputed interest | (305) |  |  | (127) |
Present value of lease liabilities | $ | 1,974 |  |  | $ | 1,785 |
Manufacturing and Supply Agreement In March 2023, the Company entered into a manufacturing and supply agreement (Novartis Agreement) with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company’s CT-0508 product candidate. The Novartis Agreement is for five years and shall renew automatically for additional one-year periods unless and until terminated by either party. In addition to paying to manufacture the product, the Company will also pay $1.0 million per calendar year, payable in quarterly payments, for reserved capacity starting on the date on which the Novartis site is declared ready to produce CT-0508 as determined by the Company. In the event of termination without cause by the Company, a termination fee equal to $4.0 million will be payable by Carisma to Novartis which, pursuant to the terms of the agreement, can be credited in full against amounts due for a substitute product. On June 26, 2024, in furtherance of its revised operating plan, the Company terminated the Novartis Agreement. Upon termination, the Company incurred a termination fee equal to $4.0 million and recorded a $4.0 million accrued expense and corresponding prepaid asset within the accompanying unaudited consolidated balance sheet. A prepaid asset was recorded as the Company has separately agreed with Novartis that if Novartis and the Company enter into an agreement for the tech transfer of another product to Novartis on or before December 31, 2024, then the $4.0 million termination fee shall be credited in full or in part against any amounts due from the Company to Novartis under such agreement relating to the substitute product. The Company and Novartis intend to negotiate a similar agreement with respect to CT-0525 in the fall of 2024. Contingencies Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. No such loss contingencies were probable nor reasonably estimable as of June 30, 2024.

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration